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Abstract: The steadily increasing knowledge regarding pathogenetic mechanisms in 
 autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In par-
ticular, the market entry of biologics has dramatically modified the natural history of rheumatic 
chronic inflammatory diseases with a meaningful impact on patients’ quality of life. Among the 
wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment 
of non-Hodgkin’s lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil 
cytoplasmic antibodies-associated vasculitis. Nowadays, in rheumatology, RTX is also used 
with off-label indications in patients with systemic sclerosis, Sjögren’s syndrome and systemic 
lupus erythematosus. RTX is a monoclonal antibody directed to CD20 molecules expressed on 
the surfaces of pre-B and mature B lymphocytes. It acts by causing apoptosis of these cells with 
antibody- and complement-dependent cytotoxicity. As inflammatory responses to cell-associated 
immune complexes are key elements in the pathogenesis of several autoimmune rheumatic 
diseases, such an approach might be effective in these patients. In fact, RTX, by promoting the 
rapid and long-term depletion of circulating and lymphoid tissue-associated B cells, leads to a 
lower recruitment of these effector cells at sites of immune complex deposition, thus reducing 
inflammation and tissue damage. RTX is of the most interest to rheumatologists as it represents 
an important additional therapeutic approach. Thus, the advent in clinical practice of approved 
RTX biosimilars, such as CT-P10, may be of help in improving treatment access as well as in 
reducing costs.
Keywords: rituximab, rheumatoid arthritis, ANCA-associated vasculitis, systemic sclerosis, 
Sjögren’s syndrome, systemic lupus erythematosus, biologics, biosimilars, myositis, pregnancy, 
vaccination
Introduction
Rituximab (RTX) is a chimeric mouse/human monoclonal antibody that targets the 
transmembrane protein CD20 molecule on the surfaces of some but not all B cells. 
RTX by binding to CD20, that is expressed on pre-B and mature B lymphocytes, leads 
to apoptosis of these cells with antibody- and complement-dependent cytotoxicity 
(Figure 1). This mechanism of action leads, in most patients, to a selective peripheral 
B cell depletion for more than 24 weeks. However, other niches of B cells (eg, those in 
the synovium) are variably depleted. RTX has no or little effects on autoantibody levels, 
which are mainly secreted by mature plasma cells, but it is active on memory and mature 
B cells. Repopulation of peripheral B cells occurs after 6–9 months from RTX course, 
and it can be of particular utility in patients with scarce adherence to daily therapy.
Nowadays, RTX is a well-established biologic agent for the treatment of some 
rheumatic autoimmune diseases such as refractory rheumatoid arthritis (RA)1,2 and 
anti-neutrophil cytoplasmic antibodies (ANCAs)-associated vasculitis (AAV).3
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At the moment, RTX regimen is intravenous (IV) with 
slightly different dosages in rheumatic diseases rang-
ing from 1,000 mg administered 2 weeks apart in RA to 
375 mg/m2 weekly for 4 weeks in AVV. In all patients, 
premedication before each infusion with methylprednisolone 
100 mg IV, acetaminophen and antihistamines is highly 
recommended.
This review provides insight into the current on- and 
off-label use of RTX in rheumatic diseases with a focus on 
the advent of biosimilars.
RTX in RA
In 2004, the first randomized double-blind placebo-
controlled trial in patients with long-standing active RA, 
despite methotrexate treatment, demonstrated that a single 
course of two infusions of RTX, alone or in combination 
with either cyclophosphamide or continued methotrexate, 
provided significant improvement in clinical response at 
weeks 24 and 48.4
The efficacy and safety of different RTX doses plus 
methotrexate, with or without glucocorticoids, in patients 
with active RA who did not respond to disease-modifying 
antirheumatic drugs (DMARDs) were tested in the DANCER 
study.5 Both RTX doses (ie, 500 mg or 1,000 mg on days 1 
and 15) were effective and well tolerated.5
Moreover, the MIRROR study showed that RTX dose 
escalation from two doses of 500 mg to two doses of 
1,000 mg did not improve clinical response. Retreatment 
strategy from week 24 supported a sustained suppression of 
disease activity through to week 48.6
The Phase III SERENE study showed the efficacy and 
safety of RTX plus methotrexate in patients with active RA 
who were naive to prior biological treatment. RTX both 
2×500 mg and 2×1,000 mg plus methotrexate significantly 
improved clinical outcomes at weeks 24 and 48.7
Further studies in patients with RA with inadequate 
response to antitumor necrosis factor (anti-TNF) thera-
pies showed that a single course of RTX associated with 
methotrexate therapy provided significant improvements in 
disease activity and progression of radiological damage.8–10 
A sustained clinical efficacy was better maintained after two 
courses of RTX about 6 months apart.10
In 2011, a Phase IIIb open-label prospective study 
(RESET) confirmed that RTX is an effective treatment 
option for patients who have not responded to a single TNF-α 
inhibitor, particularly for seropositive patients.11–13
The MIRAR study and real-life data indicate that 
switching to RTX is a successful treatment option for patients 
with RA failing on TNF antagonists.12,14,15
Treatment with RTX (2×1,000 mg) in combination with 
MTX has been shown to be an effective treatment for patients 
with MTX-naive RA, leading to sustained improvements 
in radiographic, clinical and functional outcomes over 
2 years.16–18
Figure 1 RTX has different mechanisms of action through activation of the complement cascade which leads to a direct lyse B cells by complement-mediated cytotoxicity, 
the recognition by both Fcγ receptors and complement receptors 1 and 3 on macrophages causes phagocytosis and antibody-dependent cell-mediated cytotoxicity and 
interaction with NK cells via FcγRiii and complement receptor 3.
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; NK, natural killer; RTX, rituximab.
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RTX in AAV
AAV are rare diseases classified on the basis of both vas-
cular inflammation distribution and the presence or absence 
of granulomatosis and asthma. AAV includes microscopic 
polyangiitis (MPA), granulomatosis with polyangiitis (GPA; 
also known as Wegener’s granulomatosis) and eosinophilic 
GPA (also known as Churg–Strauss syndrome).19
RTX was approved by the Food and Drug Administra-
tion (FDA) for the treatment of patients with GPA and MPA 
in 2011.3
Two retrospective open-label studies reported remis-
sion (Birmingham Vasculitis Activity Score Modified for 
Wegener’s Granulomatosis: 0) in all the 21 AAV patients 
enrolled.20,21 Based on these successful results, the first 
seminal multicenter randomized double-blind controlled trial 
on RTX in AAV (RAVE) trial was designed.22 This study 
demonstrated that RTX therapy was not inferior to daily 
cyclophosphamide for induction of remission in severe AAV 
as a higher percentage of remission occurred in RTX-treated 
patients (64% vs 53%).22 Moreover, RTX appeared to be 
superior in patients with relapsing RA.
Results from 18-month extension of the RAVE trial 
demonstrated that a single course of RTX was as effective 
as continuous conventional immunosuppressive therapy for 
the induction and maintenance of remission in AAV.23
Further analysis of the RAVE trial showed that an 
increase in PR3-ANCA levels during remission was related 
to an increased risk of relapse, particularly among patients 
with renal involvement or alveolar hemorrhage.24
RTX was also studied for remission maintenance. 
The randomized controlled studies MAINRITSAN and 
RITAZEREM demonstrated that RTX was superior to 
azathioprine for remission maintenance in AAV, without 
increasing the adverse event rate.25,26
RTX in systemic lupus 
erythematosus (SLE)
Since B cells play a critical role in SLE, in the past 10 years, tar-
geted B cell therapies have been proposed in these patients.27
B cell depletion therapy based on RTX is still unlicensed 
for SLE, but it is used to treat early onset and refractory disease. 
The most important studies on RTX in SLE are reported in 
Table 1. RTX has not been designed for SLE patients, 
but many uncontrolled studies described its utility in SLE 
patients who are refractory to conventional treatments.28–33 
In fact, RTX is a recommended option in SLE nephritis in 
both European League Against Rheumatism (EULAR) and 
American College of Rheumatology guidelines.34
RTX failed primary end points in two randomized clinical 
trials (RCTs; EXPLORER in non-renal SLE and LUNAR 
Table 1 Results from the off-label use of RTX in SLe
Studies Study design Number of patients Drug regimen Results
Merrill et al35 Prospective
Randomized (2:1)
Double-blind
Placebo-controlled 
257 SLe RTX 1 g or placebo on 
days 1, 15, 168 and 182
extra-renal manifestations: no difference 
between RTX and placebo
Rovin et al36 Prospective
Randomized (1:1)
Double-blind
Placebo-controlled
144 SLe RTX 1 g or placebo on 
days 1, 15, 168 and 182
Primary end point: no renal response at 
week 52
Reduction in anti-dsDNA and C3/C4 levels
Leandro et al28 Prospective
Open-label study
24 SLe in most cases: RTX 1 g, 
CYC 750 mg and MPD 
250 mg 2 weeks apart
At 6 months:
BiLAG, anti-dsDNA and C3 improved
Lu et al29 Retrospective 50 SLe (45 with available 
follow-up at 6 months)
46 of 50: RTX 1 g, CYC 
750 mg and MPD 100–
250 mg 2 weeks apart
BiLAG
Remission: 42%
Partial remission: 47%
Anti-dsDNA antibody titers: decreased
C3: increased
Diaz-Lagares 
et al30
Retrospective
Multicenter
Registry
164 biopsy-proven lupus 
nephropathy
RTX with corticosteroids 
(99%) and 
immunosuppressive agents 
(76%, CYC and MMF) 
At 6 and 12 months:
Complete response: 27% and 30%
Partial response: 40% and 37%
No response: 33%
At 12 months, significant improvement in 
proteinuria, albumin and protein/creatinine ratio
Better response in type iii lupus nephropathy
worse response in nephrotic syndrome and 
renal failure at the time of RTX administration
(Continued)
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Table 1 (Continued)
Studies Study design Number of patients Drug regimen Results
Condon et al32 Cohort study
Prospective 
Observational
Monocentric
50 biopsy-proven lupus 
nephropathy
RTX 1 g and MPD 500 mg 
2 weeks apart, with MMF 
as maintenance therapy
At 52 weeks:
Responders: 90%
Complete biochemical remission: 52%
Partial biochemical remission: 34%
Relapses after 65.1 weeks (20–112) from 
remission: 12
Systemic flares: 6
witt et al33 Registry
Retrospective
Multicenter
Noninterventional
85 active SLe RTX 1 g 2 weeks apart
67: 1 course
6: 2 courses
2: 3 courses
Complete response: 46.8%
Partial response: 34.2%
No response: 19.0%
SLeDAi: 12.2 → 3.3
Clinical (tender and swollen joint counts, 
fatigue, myalgia, general well-being, Raynaud’s 
phenomenon) and laboratory (anti-dsDNA, 
complement factors, hematologic parameters, 
proteinuria): improvement
Albert et al37 Prospective
Open-label
Multicenter
24 mild and moderate 
SLe without concomitant 
immunosuppressive therapy 
RTX 1 g 2 weeks apart 1-year follow-up
in 18 patients, B cell levels in peripheral blood 
were available:
effective CD19+ B cell depletion: 17
B cell return before 24 weeks: 6
SLeDAi: improvement by week 55 in 70%
Approximately one-third of the patients 
developed human anti-chimeric antibody titers 
correlated with poor B cell depletion
Lindholm 
et al38
Retrospective
Monocentric
26 SLe with active nephritis 
(17) or autoantibody-mediated 
cytopenias (thrombocytopenia: 
10 and hemolytic anemia: 4) 
refractory to conventional 
immunosuppressive treatment
RTX 375 mg/m2/week 
for 4 weeks added 
to conventional 
immunosuppressive 
therapy
Complete B cell depletion in all patients
Complete or partial response in 11 patients 
with lupus nephritis was achieved after 
6–12 months
Significant increase in platelet count after 1 month
Complete platelet count normalization at 
6 weeks in five patients
Ramos-Casals 
et al39
Multicenter
Registry
196 with systemic autoimmune 
diseases refractory to standard 
therapies
107 SLe
91: RTX 375 mg/m2/week 
for 4 weeks
16: RTX 1 g 2 weeks apart
Mean follow-up of 26.05±1.62 months
Complete response: 47%
Partial response: 34%
No response: 24%
Relapses in responders: 25%
Deaths: 5%
vital et al40 Open-label
Monocentric
Observational
39 active SLe RTX 1 g 2 weeks apart BILAG: significantly reduced
Major clinical response: 51%
Partial clinical response: 31%
Relapse after 6–18 months: 50%
B cell numbers: no response in 21 patients after 
RTX (included seven patients with no response)
Memory B cell and plasmablast repopulation 
after 26 weeks faster in patients with 
earlier relapse 
Fernandez-
Nebro et al41
Multicenter
Retrospective
Longitudinal study
116 SLe nonresponder to 
standard therapy
65%: RTX 1 g 2 weeks 
apart
30%: RTX 
375 mg/m2/week for 
4 weeks
5%: others
After 6 months:
Complete response: 17%
Partial response: 44%
After a mean follow-up of 20.0±15.2 months:
Responses: 77.6%
Relapses: 38%
Terrier et al42 Registry
Observational
Prospective
136 SLe 60%: RTX 1 g 2 weeks 
apart
36%: RTX 375 mg/m2/week 
for 4 weeks
4%: others
Safety of estrogens in Lupus erythematosus: 
National Assessment (SeLeNA)-SLeDAi: 
improvement in 71%
Relapses in 41% of responders with a good 
response in 91% to retreatment
(Continued)
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in renal SLE).35,36 In recent years, interest in B cell therapies 
has been maintained as demonstrated by the approval of 
belimumab.
RTX is currently used for more severe forms and to 
achieve disease control rather than corticosteroid-sparing 
strategy in patients with lupus nephritis. Moreover, probably 
due to its efficacy in idiopathic autoimmune hemolytic 
anemia and idiopathic thrombocytopenia purpura (ITP), 
RTX is also used in patients with SLE complicated by 
thrombocytopenia and hemolytic anemia. RTX is less 
used in cutaneous and musculoskeletal SLE involvement. 
The efficacy of RTX in mucocutaneous manifestations 
is unclear, while RTX seems to be effective in articular 
manifestations.37–42
RTX has been also described as an effective therapy in anti-
phospholipid syndrome secondary to SLE in the prevention 
of recurrent thrombotic events.43 Scarce and non-conclusive 
data are available on neuropsychiatric SLE.39–41,44,45
A study demonstrated that a single infusion of RTX 
was as effective as multiple doses with a reduction in cost 
therapy.46 Reports suggest RTX as an induction therapy 
followed by belimumab as maintenance.47 Two prospec-
tive clinical trials (NCT02260934 and NCT02284984 
on ClinicalTrials.org) are currently ongoing to assess the 
efficacy of the sequential therapy with RTX followed by 
belimumab in SLE patients.
RTX is used differently all across Europe also for eco-
nomical reasons.48
RTX in Sjögren syndrome (SS)
Traditional immunosuppressive therapies did not show effec-
tiveness in RCTs. Nowadays, SS therapy is essentially based 
on symptomatic and supportive measures. As B cells play a 
pivotal role in SS pathogenesis, RTX has been suggested to 
be potentially useful.49 The most important studies on RTX 
in SS are listed in Table 2.
A meta-analysis published in 2016 evaluated 276 subjects 
(145 RTX and 131 placebo) from four RCTs: no statistically 
significant change regarding lacrimal gland function, as 
assessed by Schirmer test, was noted while an improvement 
in salivary gland production and fatigue were described at 
24 weeks.50–53
Carubbi et al54 reported on 41 patients with SS an 
improvement at 120 weeks in unstimulated saliva flow rate 
and a decrease in labial salivary gland lymphocytic infiltra-
tion as assessed by focus score in patients treated with RTX 
compared to patients treated with conventional therapies.
RTX has been demonstrated to be effective at 
6 months as assessed by both the SS responder index and 
ultrasonography.55,56
According to recently published SS treatment recommen-
dations, RTX should be used in selected patients who have 
not responded to conventional therapies for sicca syndrome 
and for some extra-glandular manifestations (vasculitis, 
arthritis, lung involvement, peripheral neuropathy and parotid 
involvement).57
Treatment with belimumab could decrease B cell-
activating factor (BAFF) levels, B cell hyperactivation and 
salivary gland B cell infiltration. Sequential treatment with 
belimumab and RTX has been suggested.58,59 Synergic action 
of RTX and belimumab is now under investigation also in 
other rheumatic conditions (NCT02260934, NCT02631538 
and NCT02284984 on ClinicalTrials.org).
A retrospective study by a Taiwanese group on 10 patients 
with SS complicated by interstitial lung disease treated with 
RTX reported pulmonary involvement stabilization.60
RTX retreatment seems to be reasonable in patients who 
responded to first course with RTX, as reported by two dif-
ferent groups.61,62
It would be extremely important to identify predictor 
factors for RTX response. Moreover, the most adequate RTX 
regimen should be assessed throughout a specific trial.
Table 1 (Continued)
Studies Study design Number of patients Drug regimen Results
Pinto et al45 Prospective
Observational
Multicenter
42 severe and refractory SLe RTX 1 g 2 weeks apart Reduction in steroid requirement at 24 months
At 12-month follow-up, remission according to 
proteinuria:
Complete: 28%
Partial: 36%
At 12-month follow-up, remission according to 
creatinine clearance:
Complete: 12.5%
Partial: 33%
No RTX reinfusion required: 80%
Abbreviations: BiLAG, British isles Lupus Assessment Group; CYC, cyclophosphamide; MMF, mycophenolate mofetil; MPD, methylprednisolone; RTX, rituximab; SLe, 
systemic lupus erythematosus; SLeDAi, Systemic Lupus erythematosus Disease Activity index.
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Table 2 Results from the off-label use of RTX in SS
Studies Study design Number of patients Drug regimen Results
Dass et al50 Randomized
Double-blind
Placebo-controlled
17 pSS and fatigue 
vAS .50
RTX 1 g 2 weeks 
apart or placebo
At 6-month follow-up:
Fatigue vAS: reduction .20% in RTX
HRQOL: SF-36 better in RTX
Meijer et al51 Randomized (2:1)
Double-blind
Placebo-controlled
30 active pSS and a 
rate of SwS secretion 
$0.15 mL/minute
RTX 1 g 2 weeks 
apart or placebo
Follow-up at 5, 12, 24, 36 and 48 weeks
Primary end point:
SwS: better in RTX
Secondary end points:
Laboratory (B cell and RF): better in RTX
Subjective variables (MFi and vAS): better in RTX
extra-glandular manifestations: better in RTX
Better when compared to baseline values: SwS, B cell, RF, UwS, 
lacrimal gland function, MFi, SF-36 and sicca vAS
Devauchelle-
Pensec et al52
Randomized (1:1)
Placebo-controlled
Multicenter 
120 recent-onset or 
systemic pSS with 
50 mm or greater on 
at least 2 of 4 vAS 
(global disease, pain, 
fatigue, dryness)
RTX 1 g 2 weeks 
apart or placebo
At 24 weeks
Primary end points:
improvement of at least 30 mm in 2 of 4 vAS by week 24: 
no difference
Some subjective efficacy with RTX before 24 weeks 
Carubbi et al54 Prospective
Multicenter
41 pSS with early 
and active disease 
(eSSDAi $6) 
RTX or DMARDs Follow-up for 120 weeks (at weeks 12, 24, 48, 72, 96 and 120):
eSSDAi: better in RTX
Other clinical parameters (self-reported global disease 
activity pain, sicca symptoms and fatigue vAS, UwS and 
Schirmer’s i test): better with RTX
Minor salivary gland biopsies at baseline and at week 120: 
glandular infiltrate receded with RTX
Jousse-Joulin 
et al56
Randomized (1:1)
Double-blind
Placebo-controlled 
Multicenter
28 recent-onset or 
systemic pSS with 
50 mm or greater on 
at least 2 of 4 vAS 
(global disease, pain, 
fatigue, dryness)
RTX 1 g 2 weeks 
apart or placebo
At 6-week follow-up:
Salivary gland echostructure: better in RTX (50% vs 7%)
Gland sizes: no change
vascularization: no change
Gottenberg 
et al61 
Registry
Prospective
78 pSS with systemic 
or severe glandular 
involvement
86%: RTX 1 g 
2 weeks apart
14%: RTX 
375 mg/m2/week 
for 4 weeks
Follow-up every 6 months for 5 years (78 patients with at least 
one follow-up)
eSSDAi: decreased
Median dosage of corticosteroid: decreased
41 retreatments
Meiners et al62 Retrospective 15 pSS RTX 1 g 2 weeks 
apart for two 
courses
Median interval 
between courses: 
103 weeks
Follow-up at 24 and 48 weeks after RTX treatment
Better after both courses with RTX: eSSDAi, B cells, RF, MFi, igG
Improved significantly after first course but with a trend after 
second one: patient GDA and oral dryness vAS
Improved significantly only after first course: ocular dryness VAS
SWS: stable during the first 24 weeks of both courses, but with a 
significant at week 48 of the first course
Less pronounced deterioration after the treatment course
Cornec et al63 Open-label (group i)
Placebo (group ii)
45 pSS Group i (14): 
low-dose RTX 
(two 375 m2)
Group ii: 
full-dose RTX 
(two 1,000 g) (17) 
vs placebo (14)
At 24 weeks:
SSRi-30: 50% in both RTX groups
BCD duration: similar in both groups
BCD duration: not associated with clinical response
Responders: lower baseline proportions of SG B cells
Baseline serum BAFF: correlated with the proportion of SG 
B cells and clinical response (higher levels in nonresponders)
Delli et al64 Randomized (2:1)
Double-blind
Placebo-controlled
20 RTX-treated and 
10 placebo-treated pSS
RTX 1 g 2 weeks 
apart or placebo
Biopsies at baseline and 12 weeks after treatment:
B cells, number and the severity of lymphoepithelial lesions and 
germinal centers: reduced in RTX
T cells (CD3+): no change
CD20+ higher in responders
Abbreviations: BAFF, B cell-activating factor; BCD, B cell depletion; DMARDs, disease-modifying antirheumatic drugs; eSSDAi, eULAR Sjögren’s syndrome disease activity 
index; eULAR, european League Against Rheumatism; GDA, global disease activity; HRQOL, health-related quality of life; MFi, multidimensional fatigue inventory; pSS, 
primary SS; RF, rheumatoid factor; RTX, rituximab; SF-36, 36-item Short Form Health Survey; SG, salivary gland; SS, Sjögren syndrome; SSRi, SS responder index; SwS, 
stimulated whole saliva; UwS, unstimulated whole saliva; vAS, visual Analog Scale.
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Salivary gland B cell infiltration would be important to 
determine the efficacy of RTX even if its role has not yet 
been completely elucidated; the studies published are difficult 
to be compared as they report opposite results but they do 
significantly differ about methodology.63,64
Many reasons could be evoked to explain why biological 
therapies are ineffective in SS randomized trials. In a recent 
paper, the authors gave many possible explanations: incorrect 
diagnosis, nonrepresentative SS population enrolled in clinical 
trials, antinuclear antibody (ANA) false negativity, lack of 
marker for fatigue and other benign symptoms, and an unknown 
link between immune system and central nervous system.65
RTX in systemic sclerosis (SSc)
B cells play a central role in SSc pathogenesis. A mounting 
quantity of evidences provides a rationale for the use of 
RTX in SSc patients.66–68 The most significant studies on 
RTX in SSc are reported in Table 3.
RTX was initially administered in patients affected by 
chronic graft-versus-host disease with a good response on 
skin fibrosis but not on extra-cutaneous manifestations.69
Uncontrolled studies and case reports described the 
efficacy of RTX in SSc patients with regard to pulmonary 
function, skin fibrosis, and less frequently arthritis, calcinosis 
and quality of life.70–80
A retrospective case–control analysis performed by the 
European Scleroderma Trial and Research Group described 
63 SSc patients treated with RTX matched to 25 controls; 
authors described an improvement in skin involvement as 
assessed by modified Rodnan skin score and a stabilization 
of lung function as assessed by pulmonary lung function.81
Bosello et al82 described, in a cohort of 20 SSc patients, 
the effectiveness of RTX with regard to skin fibrosis and 
disease activity.
A recent published work by Daoussis et al83 showed a 
beneficial effect on lung involvement of RTX on 33 patients 
with a follow-up up to 7 years.
Due to heterogeneity of these studies (different dosages 
and modalities of administration, number of cycles and 
follow-up period, indications and end points) it would be 
very problematic to draw definitive conclusions. Not enough 
data are currently available in the literature to prescribe 
Table 3 Results from the off-label use of RTX in SSc
Studies Study design Number of 
patients
Drug regimen Results
Lafyatis 
et al71
Open-label
Observational
15 dcSSc RTX 1 g 2 weeks apart Primary outcome:
Change in mRSS at 6 months: no change
Secondary outcomes:
PFTs: stable
Organ involvement: stable
B cell infiltrates: depleted (vs baseline)
Autoantibodies: modest changes
Bosello 
et al72
Open-label 9 SSc RTX 1 g 2 weeks apart Follow-up up to 36 months (skin biopsy at baseline and during 
the follow-up):
After 6 months; skin score, disease activity index and disease 
severity index: decreased
iL-6: reduced
Serum B cells: reduced in seven patients
B cells at baseline in three patients
Daoussis 
et al73
Open-label 8 dcSSc with iLD RTX 375 mg/m2/week for 
4 weeks
Long-term (2 years) safety and efficacy:
Lung involvement (PFTs and HRCT): improved
Skin involvement (mRSS and myofibroblast): improved
Smith et al74 Open-label 8 dcSSc RTX 1 g 2 weeks apart 24-week follow-up:
Peripheral CD19+: reduced
Skin sclerosis score: reduced
Biopsies (dermal hyalinized collagen content and dermal 
myofibroblast numbers): change
Smith et al75 Open-label 8 dcSSc RTX 1 g 2 weeks apart at 
baseline and after 6 months
2-year follow-up:
mRSS: decreased
DAS: decreased
internal organ involvement: stable
B cell depletion
Biopsies (hyalinized collagen score): change
(Continued)
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Table 3 (Continued)
Studies Study design Number of 
patients
Drug regimen Results
Moazedi-
Fuerst et al76 
Open-label 5 SSc with iLD 
nonresponders 
to CYC
RTX 500 mg 2 weeks apart 
every 3 months for 1 year
mRSS: decreased
DLCO and FvC: increased
Lung fibrosis (three patients): decreased
Digital ulcerations: healed
Severity of Raynaud’s phenomenon and vascular pain: decreased
Number of capillary bleeds and megacapillaries: decreased
B-lymphocyte count decreased
Serum immunoglobulins, autoantibody titers or CRP levels: 
no change
Giuggioli 
et al77
Open-label 10 SSc One or more cycles of RTX 
375 mg/m2/week for 4 weeks
Follow-up at 6 months and at last follow-up (up to 72 months):
mRSS: decreased at 6 months
Other cutaneous manifestations (hypermelanosis, pruritus, 
calcinosis): improved
Arthritis: improved
iLD: stable in 6 and worsened in 2
Pro-inflammatory cytokines: a more or less pronounced 
reduction after the first RTX cycle
Daoussis 
et al78
Randomized 14 SSc 8: RTX 375 m2 weekly for 
4 weeks at baseline and 
at 24 weeks plus standard 
therapy
6: standard treatment alone
1-year follow-up:
FvC, DLCO and skin involvement: increased
Jordan et al81 Registry
Case–control
88 SSc 63: RTX 1 g 2 weeks apart
25: controls
Primary end point:
mRSS: reduced better in RTX
Secondary end points:
FvC: no further decline
Safety measures: good 
Bosello 
et al82
Open-label 29 dcSSc with or 
without iLD
RTX 1 g 2 weeks apart 
(more courses when needed)
Follow-up up to 68.9 months:
Skin score, activity and severity indices improved significantly 
after 12 months and at final follow-up compared to baseline
FvC and TLC: increased
DLCO: stable
HRCT: stable in 80% of patients
Daoussis 
et al83
Multicenter
Open-label
51 SSc with iLD 33: RTX 375 m2 weekly for 
4 weeks
18: conventional therapy
Median follow-up 4 years (up to 7 years):
FVC: increased at 2-year follow-up, results confirmed at 
7 years
mRSS: outcome favorable to RTX at all times
Abbreviations: CRP, C-reactive protein; CYC, cyclophosphamide; DAS, Disease Activity Score; dcSSc, diffuse cutaneous SSc; DLCO, carbon monoxide diffusing capacity; 
FvC, forced vital capacity; HRCT, high-resolution computed tomography; iL-6, interleukin-6; iLD, interstitial lung disease; mRSS, Rodnan skin thickness score; PFTs, pulmonary 
function tests; RTX, rituximab; SSc, systemic sclerosis; TLC, total lung capacity.
RTX in SSc patients who are naive to conventional therapy. 
RTX treatment seems to be promising in lung, skin and 
articular involvement secondary to SSc. There are little 
data on calcinosis, where RTX can be considered as a 
rescue therapy. A prospective, placebo-controlled, ran-
domized trial is needed to definitively assess the efficacy 
of RTX in SSc. Meanwhile, RTX can be considered as a 
valid option in those patients who cannot tolerate or have 
contraindications for conventional therapies (ie, cyclo-
phosphamide) or in patients where conventional therapies 
have already failed. RTX would be useful in pulmonary 
involvement as a maintenance therapy after induction with 
cyclophosphamide.
RTX in spondyloarthritis
The efficacy of RTX has also been tested in spondyloar-
thritis. A prospective open-label study showed that, among 
20 patients with ankylosing spondylitis, 40% of anti-TNF-
naive patients (N=10) achieved an improvement in Assess-
ment of SpondyloArthritis international Society (ASAS) and 
50% in Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI), while RTX did not seem to be effective in the 
TNF failure (N=10).84 Moreover, the same authors reported 
that five patients who flared on follow-up responded again 
when retreated with RTX.85
Thus, these studies include a small number of patients 
and are open label, and no clear conclusions can be drawn. 
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Further studies are needed to ascertain the real therapeutic 
role of RTX.
Idiopathic inflammatory 
myopathies (IIMs)
IIMs include adult polymyositis (PM) and dermatomyositis 
(DM), juvenile PM and DM, anti-synthetase syndrome (ASS) 
and inclusion body myositis.
According to 2012 Cochrane review focused on therapy 
in DM and PM, no adequately designed study is present in 
the literature to assess which immunosuppressive drug is 
the best corticosteroid-sparing agent.86 As a result, the drug 
choice is often based on empirical considerations.
Since up to 80% of patients with IIMs show circulating 
autoantibodies and B cells that are found within inflamed 
muscle fibers, RTX therapy seems to be reasonable.87
Although the use of RTX in IIMs is rational and several 
uncontrolled trials suggested its utility, the RTX in myositis 
(RIM) trial, conducted on 195 patients, failed to reach both 
primary and secondary end points;88 however, almost 80% 
of patients responded to RTX treatment.
A subanalysis of RIM trial also demonstrated RTX as 
effective in refractory skin involvement in patients with both 
adult and juvenile DM.89
Some evidence suggests that RTX might be useful in 
interstitial lung disease secondary to IIMs, especially when 
related to ASS.90–93
The presence of antibodies predicts a good response to 
RTX.94,95 Moreover, their titers decrease after therapy with vari-
able correlation with disease activity and muscle enzyme.96
RTX biosimilars
RTX patents expired in Europe in 2013 and in the USA in 
2016. Various Phases I, II and III clinical trials are ongo-
ing (JHL1101, ABP 798, MabionCD20, PF-05280586, 
RTXM83, SAIT101, CT-P10, GP-2013).
European Medicines Agency (EMA) has recently 
approved the first RTX biosimilar, CT-P10, in RA. In the 
pivotal trial, patients with active RA were randomly assigned 
(2:1), to receive CT-P10 1,000 mg or RTX 1,000 mg 2 weeks 
apart. Patients were randomized to receive the treatment 
(50 patients for each group). Additional 50 patients were 
recruited to the CT-P10 group to better assess its safety. 
CT-P10 was demonstrated to be equivalent regarding phar-
macokinetics and efficacy with similar immunogenicity and 
safety profiles as the originator.97
Moreover, patients who completed the follow-up at 
72 weeks (N=87: 58 in the CT-P10 group and 29 in the 
RTX group) entered into the open-label extension study for 
56 weeks. Patients of each group received CT-P10 according 
to DAS28. Patients who switched from RTX to CT-P10 dem-
onstrated comparable efficacy and safety profiles compared 
to those who maintained CT-P10. In RA patients, maintained 
CT-P10 was also well tolerated and effective up to 2 years.98
EMA is also currently evaluating GP2013 in RA. GP2013 
has been demonstrated to be comparable to the originator in 
a trial recently published as an abstract.99
PF-05280586 was proven to be similar to the EU and US 
originator with regard to pharmacokinetics, CD19 deple-
tion, antidrugs antibodies production and adverse events in 
RA patients.100
Moreover, RTX biosimilars (BCD-020, Baball and 
MabTas) have been licensed in countries where regula-
tory processes are not as strict as FDA and EMA recom-
mendations.
Of note, other biosimilars (ie, infliximab and etanercept) 
have been successfully introduced in the treatment of RA. 
Biosimilars have no clinical meaningful differences, in 
terms of efficacy and safety with respect to the originator; 
thanks to cost saving, they should be considered and their use 
should be promoted. The availability of biosimilars would 
allow patients to receive medications that might otherwise 
be unaffordable to them.101
RTX in pregnancy
RTX was shown not to have any teratogenic effect in 
animals.102 In human beings, when RTX is administered 
during the second and third trimester, similar levels are found 
in mother and cord blood.103,104
Chakravarty et al105 reported 153 pregnancies exposed to 
RTX in patients affected by RA, non-Hodgkin lymphoma and 
other autoimmune diseases: 90 live births (22 premature and 
one extremely premature births), 33 miscarriages, 28 elective 
terminations, one late fetal loss and one maternal death due 
to cerebral hemorrhage in idiopathic thrombocytopenic pur-
pura. Among live births, two congenital malformations, one 
death for unknown causes (at 6 months), 11 hematological 
abnormalities without infectious complication and four neo-
natal infections were reported.105 In particular, 21 patients 
received RTX during the second or third trimester, among 
them no maternal death, neonatal death or congenital mal-
formations were noted, whereas cytopenia was reported in 
seven newborns.105
RTX exposure before conception or during early preg-
nancy does not provoke B cell depletion in newborns, 
whereas during the late stage of pregnancy (second and 
third trimester) RTX is able to reduce B cells that usually 
normalize after 3–6 months. Mothers and newborns, exposed 
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to RTX during second and third trimester, should be moni-
tored for the risk of infections since neutropenia and B cell 
depletion have been described in newborns.104,106–108
Although no fetus damage has been reported in pregnan-
cies exposed to RTX during the first trimester, this therapy, 
according to EULAR recommendations, should be consid-
ered only when no other therapeutic option is available.
According to the British Society of Rheumatology (BSR) 
and British Health Professionals in Rheumatology(BHPR) 
guidelines on prescribing drugs in pregnancy and breastfeed-
ing, an effective contraception is recommended while taking 
RTX and for 12 months following treatment.109
According to EULAR recommendations, when RTX is 
administered before week 22, vaccinations can be performed 
according to local guidelines (live vaccines included). 
When administered later in pregnancy, live vaccines should 
be avoided till 6 months of life. Due to the lack of data, 
lactation should be avoided.110
Miscellaneous
RTX has been shown to impact on vaccine immunogenic-
ity, thus highlighting the importance of the right timing 
of vaccines in relation to RTX administration.111 For this 
reason, the better results in terms of humoral response are 
reported 6 months or more after RTX dosing.112,113 Vacci-
nations should be considered at least 4 weeks before RTX 
administration. In particular, a significant humoral response 
impairment has been reported for influenza and pneumococ-
cal vaccinations.112–117 No data are available on the effects of 
RTX on hepatitis B virus (HBV), human papilloma virus or 
yellow fever vaccines. Safety for live vaccines has not been 
studied in patients treated with RTX; thus, these vaccines 
are considered contraindicated in this setting.
Screening serologies for HBV and hepatitis C virus 
(HCV) must be undertaken even if resolved HBV hepatitis 
reactivation has been rarely reported.118,119
In patients with HBsAg and anti-HBc negativity, vaccina-
tion should be considered before RTX initiation. By contrast, 
patients who are HBsAg and/or anti-HBc positive should be 
referred to a hepatologist for consideration of a prophylactic 
therapy, and HBV DNA levels have to be closely monitored 
if RTX is administered.118,119
With regard to HCV, RTX is used in the treatment of 
HCV-induced cryoglobulinemia. HCV should be screened, 
and for chronic HCV carriers, collaboration with a hepatolo-
gist is mandatory to plan a treatment strategy.18,120
Before RTX administration, routine screening for tuber-
culosis is suggested, even if it is not currently believed to 
be necessary. Patients with active tuberculosis should be 
appropriately treated and RTX should not be initiated.121
The long-term RTX safety report highlighted that seri-
ous opportunistic infections were rare. Among these, the 
reactivation of the John Cunningham (JC) virus leading 
to progressive multifocal leukoencephalopathy has been 
reported in patients with autoimmune diseases who should 
be informed of this risk.122
Finally, it is well known that long-term RTX adminis-
tration is associated with hypogammaglobulinemia whose 
consequences are still unclear. It is recommended to evaluate 
baseline immunoglobulin levels and to consider cessation of 
therapy when the IgG level drops progressively.123
Moreover, attention should be paid to late-onset neu-
tropenia that has been described as a potential RTX-related 
adverse event.124
Conclusion
RTX is currently considered useful and a relatively safe bio-
logical agent in the treatment of some rheumatic diseases.
Although RTX has been demonstrated to be relatively 
safe for infections, particular attention should be paid in the 
presence of HBV for the risk of reactivation.
Pregnancy during RTX treatment should be avoided since 
RTX, especially when administered during second and third 
trimester, increases the risk of infection in the mother and 
in the newborn.
RTX has been demonstrated useful in RA and AAV, and 
it is currently approved in many countries with these indica-
tions. RTX is also administered in other rheumatic condi-
tions, such as SLE, SS and SSc, refractory to conventional 
therapies, but its utility in these conditions has not yet been 
completely and fully elucidated.
Moreover, further studies are needed to clarify some 
controversial points such as the association with concomitant 
DMARDs, RTX dosage and the optimal interval for retreat-
ment. The availability of approved RTX biosimilars, such as 
CT-P10, would allow a widespread access of this treatment 
with cost saving. More likely, the harmonization of guidelines 
and recommendations on the use of biosimilars will be of 
help in clinical practice.
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